✦ LIBER ✦

361 Anti-tumor Efficacy Profile of a Novel Dual PI3K/mTOR Inhibitor, DS-7423

✍ Scribed by Hirota, Y.; Sato, K.; Hama, Y.; Nagashima, Y.; Watanabe, R.; Suzuki, N.; Sugimura, M.; Shiose, Y.

Book ID: 122549019
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 60 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(12)72159-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

362 Anti-tumor Efficacy of DS-7423, a No

362 Anti-tumor Efficacy of DS-7423, a Novel PI3K/mTOR Dual Inhibitor, in Ovarian Clear Cell Adenocarcinoma

✍ Kashiyama, T.; Oda, K.; Ikeda, Y.; Shiose, Y.; Hirota, Y.; Miyasaka, A.; Wada-Hi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 76 KB

363 A Dual PI3K/mTOR Inhibitor DS-7423 i

363 A Dual PI3K/mTOR Inhibitor DS-7423 is Effective in in Vitro and in Vivo Models of Glioblastoma Cell Lines and Glioma Stem Cells

✍ Koul, D.; Wang, S.; Fu, J.; Yao, J.; Yung, W.K. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

ChemInform Abstract: Identification of G

ChemInform Abstract: Identification of GNE-477 (I), a Potent and Efficacious Dual PI3K/mTOR Inhibitor.

✍ Timothy P. Heffron; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 18 KB

PP 25 Preclinical efficacy of a dual PI3

PP 25 Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer

✍ N. Dey; H. Wu; Y. Sun; P. De; B. Leyland-Jones 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Dietary flavonoid fisetin: A novel dual

Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management

✍ Vaqar Mustafa Adhami; Deeba Nadeem Syed; Naghma Khan; Hasan Mukhtar 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 348 KB

The efficacy of a novel, dual PI3K/mTOR

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

✍ Niranjan Awasthi; Peter L. Yen; Margaret A. Schwarz; Roderich E. Schwarz 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB

## Abstract Gemcitabine has limited clinical benefits for pancreatic ductal adenocarcinoma (PDAC). The phosphatidylinositol‐3‐kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways are frequently dysregulated in PDAC. We investigated the effects of NVP‐BEZ235, a novel dual PI